Shih-Chieh Chang, Cheng-Yu Chang, Chiung-Yu Chen, Chong-Jen Yu

Slides:

Advertisements

Similar presentations

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Advertisements

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD

Jeffrey Bradley, MD Journal of Thoracic Oncology

Lung cancer screening with low-dose computed tomography: Experiences from a tertiary hospital in Taiwan Chih-Yu Chen, Chia-Hung Chen, Te-Chun Shen, Wen-Chien.

Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.

Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia Hiroaki Tachi, MD, Toshihiro Shiozawa, MD, Chio Sakai, MD, Mariko Kasuga,

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Eisaku.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Lungs on Fire Journal of Thoracic Oncology

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion Eckart Laack, MD, Ronald.

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation Vienna Ludovini, PhD,

Electronic Updates for JTO Readers

Primary Pulmonary Choriocarcinoma Presenting with a Hemothorax

Joline S. W. Lind, MBBS, Egbert F

The Moth-Eaten Lung Journal of Thoracic Oncology

Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma Kazuhisa Nakashima, MD, Tateaki Naito, MD, Shota Omori, MD, Shusuke Yoshikawa,

An Unusual Presentation of Malignant Pleural Mesothelioma

Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Primary Tracheal Lymphoma Causing Respiratory Failure

Frank Detterbeck, MD Journal of Thoracic Oncology

Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer Max Dahele, MBChB, MSc, David Palma, MD, Frank Lagerwaard, MD, PhD, Ben Slotman,

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Multiple Pulmonary Chondromas in a Young Female Patient: A Component of Carney Triad Gui-Bin Qiao, MD, PhD, Wei-Sheng Zeng, MD, Li-Jun Peng, MD, Wen-Zhao.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Multiple Pulmonary Chondroid Hamartoma

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Vamsidhar Velcheti, MD, Manmeet Ahluwalia, MD

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Frequency of Lymph Node Metastasis According to the Size of Tumors in Resected Pulmonary Adenocarcinoma with a Size of 30 mm or Smaller Yangki Seok,

A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib Oliver Gautschi, MD, Chantal Pauli, MD, Klaus Strobel, MD, Astrid Hirschmann,

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor–Mutated Lung Cancer Treated with Two Cycles of Erlotinib Brendan.

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

The Role of Surgery in the Management of Primary Thymic Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Kimihiro Shimizu, MD, PhD, Izumi Takeyoshi,

Jennifer L. Dallas, MD, Michael A. Jantz, MD, Judith L

Long-term remission of hepatic hydrothorax after OK-432 pleurodesis

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Drug Interaction Between Complementary Herbal Medicines and Gefitinib

CT Features of Epidermal Growth Factor Receptor–Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma Mizue Hasegawa, MD, PhD,

Jeffrey Bradley, MD Journal of Thoracic Oncology

Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns Kuo-Hsuan Hsu, MD, Kun-Chieh Chen, MD,

Multiple Pulmonary Nodules in an Elderly Woman

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Bronchioloalveolar Carcinoma Presenting as Chronic Progressive Pulmonary Infiltrates in a Woman with HIV: A Diagnosis Worth Making Todd M. Erickson,

European Lung Cancer Conference (ELCC) 2016 Organisation

Recurrent Primary Synovial Sarcoma of the Chest Wall

Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,

Tetsuzo Tagawa, MD, Miyuki Takasu, MD, Teruyoshi Ishida, MD

Cristiano Rampinelli, MD, Vittoria Vecchi, MD, Massimo Bellomi, MD

Journal of Thoracic Oncology

Acute Exacerbation of Interstitial Fibrosis After Pulmonary Resection

A and B, Computed tomography (CT) of the chest prior to cabozantinib therapy demonstrated a dominant mass in the left upper lobe (B, black arrow), measuring.

David Garfield, MD Journal of Thoracic Oncology

Popcorn in the Lung Journal of Thoracic Oncology

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure Joel P. Womack,

Gefitinib-Associated Propionibacterium acnes Pleural Empyema

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Successful Erlotinib Rechallenge after Gefitinib-Induced Acute Interstitial Pneumonia Shih-Chieh Chang, Cheng-Yu Chang, Chiung-Yu Chen, Chong-Jen Yu Journal of Thoracic Oncology Volume 5, Issue 7, Pages 1105-1106 (July 2010) DOI: 10.1097/JTO.0b013e3181dc39cd Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A, Chest computed tomography (CT) showed diffuse ground-glass opacity over lower lung zones (arrows) and pleural effusion on the sixth week of gefitinib therapy. B, Chest CT performed on 48th day of erlotinib therapy showed multiple small residual lung tumors. Journal of Thoracic Oncology 2010 5, 1105-1106DOI: (10.1097/JTO.0b013e3181dc39cd) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 A, The chest computed tomography (CT) showed decreased size of the main tumor (thick arrow) and diffuse ground-glass opacity over upper lung zones (thin arrows) on the seventh week of gefitinib therapy. B, The chest CT performed on the 131th day of erlotinib therapy showed partial remission of right upper lung tumor (arrow). Journal of Thoracic Oncology 2010 5, 1105-1106DOI: (10.1097/JTO.0b013e3181dc39cd) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions